WuXi Biologics (2269.HK), a global company with open-access biologics technology platforms, announced on Wednesday that it has been named a winner of the 2021 CMO Leadership Awards.
The company has been recognised for the fourth consecutive year. It was honoured in six award categories, capabilities, compatibility, expertise, quality, reliability, and service, and across the respondent groups - Big Pharma, Small Pharma, and Overall (combined Big and Small Pharma).
The firm was chosen based on research from Industry Standard Research's Contract Manufacturing Quality Benchmarking annual online surveys with over 70 contract manufacturing organisations assessed on more than 23 different performance metrics. Research participants were recruited from Pharma and Biopharma companies of all sizes and were screened for decision-making influence related to working with contract manufacturing suppliers.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business